Zhimeng Biopharma’s Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
Shanghai Zhimeng Biopharma, Inc. (“Zhimeng Biopharma”), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 potassium channel opener, CB03-154, has received an approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a […]